Replies to post #106608 on Biotech Values

[DewDiligence]

The threat to NVO’s franchise from biosimilars is genuine, IMO. Insulin is the simplest of all proteins. Producing knockoffs of any of the currently marketed insulin analogs ought to be a piece of cake compared to the effort MNTA/NVS undertook for Lovenox and Copaxone.

[DewDiligence]

NVO’s 2014 outlook underwhelms investors due in part to the threat from insulin FoB’s:

http://in.reuters.com/article/2014/01/30/us-novonordisk-results-idINBREA0T0M220140130

Novo Nordisk said on Thursday that it now expected sales to grow by 8-11 percent, below its average 13 percent growth rate over the last ten years. It forecast operating profit to grow by around 10 percent in local currencies.